Trial Profile
Assessment of efficy and safety of everolimus in Japanese patients with mRCC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2013
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 23 Jan 2013 New trial record